Vertex Pharmaceuticals Incorporated VRTX

NASDAQ · Healthcare · Biotechnology

$515.02

Close on Fri, 20 Nov 2026 · market value $131B

What the price is betting on

Below its record

At $515, the price assumes revenue grows about 10% a year for five years, from $13B to about $19.6B by FY2030. That is about the same as what analysts expect for the next two years and about the same as the company's own last three years.

The price assumes10%
Analysts, next two years11%
Last 3 years10%

Revenue growth a year. The price figure comes from a reverse DCF at a 6.7% discount rate.

Track it and Parra checks each report against the path, and tells you when revenue falls behind it.

Own more than VRTX? Check up to 5 of your stocks at once, free, no account.

0$10B$20B$30B$13B'22'23'24'25Sep '26'26'27'28'29'30What the price needsReportedAnalysts

Both sides

Three stories, three values

Bear

$406

Base

$507

Bull

$667

Today $515

  • Bear $406. TRIKAFTA/KAFTRIO keeps shrinking and ALYFTREK, still only a fifth of quarterly revenue, is too small to replace it. Margins keep easing from a high level, and the FY2024 loss year shows cash flow can swing sharply again. The premium valuation then has little support while growth stays low.
  • Base $507. Newer products (ALYFTREK, CASGEVY, JOURNAVX) grow fast enough to replace most, but not all, of the shrinking TRIKAFTA/KAFTRIO revenue. Cash flow grows a little more slowly than the market expects, because total revenue growth has slowed and the core medicine is now falling. Margins stay far above peers while edging down, and cash conversion stays near its FY2025 level.
  • Bull $667. ALYFTREK and CASGEVY keep growing very fast, and pipeline progress adds revenue beyond cystic fibrosis. Together they more than offset the TRIKAFTA/KAFTRIO decline. Margins and cash conversion hold near FY2025 levels. This needs growth to speed up from FY2025, and the facts do not size the new revenue.

AI-written stories, valued by code from the same model.

Checkpoints

The revenue the price needs

  1. YearNeedsAnalysts expect
  2. FY2026$13.3B$13.3B, on the path
  3. FY2027$14.6B$14.7B, on the path
  4. FY2028$16.2B$16.5B, on the path
  5. FY2029$17.8B$18.7B, on the path
  6. FY2030$19.6B$20.6B, on the path

Each year's revenue at 10% growth from $13B in the 12 months to September 2026.

At a glance

Healthcare · Biotechnology · listed on NASDAQ

Revenue, FY2025
$12B
Growth, 3 years a year
10%
Cash margin
27%
Net cash
$4.6B
Shares, 3-year change
−0.4%
Dividend yield
0%

What other healthcare prices are betting on

Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.